MX2022015611A - Ensayo basado en células para determinar la actividad de destrucción de tumores in vitro de células inmunitarias que expresan antígeno quimérico. - Google Patents
Ensayo basado en células para determinar la actividad de destrucción de tumores in vitro de células inmunitarias que expresan antígeno quimérico.Info
- Publication number
- MX2022015611A MX2022015611A MX2022015611A MX2022015611A MX2022015611A MX 2022015611 A MX2022015611 A MX 2022015611A MX 2022015611 A MX2022015611 A MX 2022015611A MX 2022015611 A MX2022015611 A MX 2022015611A MX 2022015611 A MX2022015611 A MX 2022015611A
- Authority
- MX
- Mexico
- Prior art keywords
- car
- immune cells
- cell
- chimeric antigen
- determining
- Prior art date
Links
- 210000002865 immune cell Anatomy 0.000 title abstract 4
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 238000000338 in vitro Methods 0.000 title abstract 2
- 238000000423 cell based assay Methods 0.000 title 1
- 230000005909 tumor killing Effects 0.000 title 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 5
- 210000004027 cell Anatomy 0.000 abstract 3
- 239000013068 control sample Substances 0.000 abstract 2
- 239000000523 sample Substances 0.000 abstract 2
- 230000030833 cell death Effects 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
- G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/686—Anti-idiotype
Abstract
La descripción proporciona un método in vitro para determinar la potencia (p. ej., citotoxicidad) de una célula inmunitaria que expresa una molécula de receptor de antígeno quimérico (CAR). En una muestra de prueba, las células inmunitarias que expresan CAR se incuban con células diana que expresan un antígeno que interactúa con el CAR. En una muestra de control, las células inmunitarias que expresan CAR se incuban con las células diana y una molécula inhibidora que evita la interacción entre el CAR y las células diana. La cantidad de muerte de células diana se determina tanto en la muestra de prueba como en la muestra de control y se comparan.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063036249P | 2020-06-08 | 2020-06-08 | |
US202063125173P | 2020-12-14 | 2020-12-14 | |
PCT/IB2021/054996 WO2021250552A1 (en) | 2020-06-08 | 2021-06-07 | Cell-based assay for determining the in vitro tumor killing activity of chimeric antigen expressing immune cells |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022015611A true MX2022015611A (es) | 2023-04-18 |
Family
ID=76708258
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022015611A MX2022015611A (es) | 2020-06-08 | 2021-06-07 | Ensayo basado en células para determinar la actividad de destrucción de tumores in vitro de células inmunitarias que expresan antígeno quimérico. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220057381A1 (es) |
EP (1) | EP4162269A1 (es) |
JP (1) | JP2023530238A (es) |
KR (1) | KR20230022964A (es) |
CN (1) | CN115917317A (es) |
AU (1) | AU2021288751A1 (es) |
BR (1) | BR112022025026A2 (es) |
CA (1) | CA3186600A1 (es) |
MX (1) | MX2022015611A (es) |
WO (1) | WO2021250552A1 (es) |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
JP2004511425A (ja) | 2000-02-08 | 2004-04-15 | ザ ペン ステート リサーチ ファウンデーション | 免疫療法に使用されるインターロイキン13受容体サブユニットアルファー2 |
NZ612512A (en) | 2010-12-09 | 2015-03-27 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
WO2013126720A2 (en) * | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for the assessment of target cancer cell resistance to car engineered t cell killing |
US9371396B2 (en) | 2012-06-15 | 2016-06-21 | Sinomab Bioscience Limited | Anti-CD22 anti-idiotypic antibodies and uses thereof |
US9745368B2 (en) | 2013-03-15 | 2017-08-29 | The Trustees Of The University Of Pennsylvania | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
SG11201509609SA (en) | 2013-05-24 | 2015-12-30 | Univ Texas | Chimeric antigen receptor-targeting monoclonal antibodies |
IL280215B (en) | 2014-04-07 | 2022-07-01 | Novartis Ag | Cancer treatment using a chimeric receptor antigen (car) against cd19 |
EP3712171A1 (en) | 2014-08-19 | 2020-09-23 | Novartis AG | Treatment of cancer using a cd123 chimeric antigen receptor |
WO2018111340A1 (en) * | 2016-12-16 | 2018-06-21 | Novartis Ag | Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells |
CN110662771B (zh) * | 2018-02-01 | 2023-07-28 | 南京驯鹿生物技术股份有限公司 | 一种结合bcma的嵌合抗原受体(car)及其应用 |
WO2020051345A1 (en) * | 2018-09-05 | 2020-03-12 | Memorial Sloan-Kettering Cancer Center | Pleural effusion-based methods for assessing immunoresponsive cell activity |
-
2021
- 2021-06-07 JP JP2022575355A patent/JP2023530238A/ja active Pending
- 2021-06-07 MX MX2022015611A patent/MX2022015611A/es unknown
- 2021-06-07 BR BR112022025026A patent/BR112022025026A2/pt unknown
- 2021-06-07 US US17/340,296 patent/US20220057381A1/en active Pending
- 2021-06-07 CN CN202180049139.3A patent/CN115917317A/zh active Pending
- 2021-06-07 WO PCT/IB2021/054996 patent/WO2021250552A1/en active Application Filing
- 2021-06-07 EP EP21736374.6A patent/EP4162269A1/en active Pending
- 2021-06-07 KR KR1020237000624A patent/KR20230022964A/ko unknown
- 2021-06-07 AU AU2021288751A patent/AU2021288751A1/en active Pending
- 2021-06-07 CA CA3186600A patent/CA3186600A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2023530238A (ja) | 2023-07-14 |
CN115917317A (zh) | 2023-04-04 |
CA3186600A1 (en) | 2021-12-16 |
US20220057381A1 (en) | 2022-02-24 |
KR20230022964A (ko) | 2023-02-16 |
AU2021288751A1 (en) | 2023-02-09 |
EP4162269A1 (en) | 2023-04-12 |
WO2021250552A1 (en) | 2021-12-16 |
BR112022025026A2 (pt) | 2023-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Guan et al. | Inducible indoleamine 2, 3-dioxygenase 1 and programmed death ligand 1 expression as the potency marker for mesenchymal stromal cells | |
Tarhini et al. | Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab | |
Häusler et al. | Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion | |
Müller-Durovic et al. | Killer cell lectin-like receptor G1 inhibits NK cell function through activation of adenosine 5′-monophosphate–activated protein kinase | |
van Loosdregt et al. | Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity | |
Chan et al. | Antigen affinity controls rapid T-dependent antibody production by driving the expansion rather than the differentiation or extrafollicular migration of early plasmablasts | |
Mata et al. | Effects of cryopreservation on effector cells for antibody dependent cell-mediated cytotoxicity (ADCC) and natural killer (NK) cell activity in 51Cr-release and CD107a assays | |
Sharma et al. | Protein acyltransferase DHHC3 regulates breast tumor growth, oxidative stress, and senescence | |
Sapoznik et al. | CXCR1 as a novel target for directing reactive T cells toward melanoma: implications for adoptive cell transfer immunotherapy | |
Grage-Griebenow et al. | L1CAM promotes enrichment of immunosuppressive T cells in human pancreatic cancer correlating with malignant progression | |
US20100167315A1 (en) | Method for investigating the response to a treatment with a monoclonal antibody | |
Deisting et al. | Impact of diverse immune evasion mechanisms of cancer cells on T cells engaged by EpCAM/CD3-bispecific antibody construct AMG 110 | |
Zhu et al. | Prohibitin regulates TGF‐β induced apoptosis as a downstream effector of smad‐dependent and‐independent signaling | |
Appleby et al. | Characterization of a distinct population of circulating human non-adherent endothelial forming cells and their recruitment via intercellular adhesion molecule-3 | |
Tomogane et al. | Human Vγ9Vδ2 T cells exert anti-tumor activity independently of PD-L1 expression in tumor cells | |
Blunt et al. | Phenotypic characterization of bovine memory cells responding to mycobacteria in IFNγ enzyme linked immunospot assays | |
Vallion et al. | Regulatory T cell stability and migration are dependent on mTOR | |
Jiang et al. | Stimulation of prostate cells by the senescence phenotype of epithelial and stromal cells: Implication for benign prostate hyperplasia | |
US20200333324A1 (en) | Method of predicting clinical outcome of anticancer agents | |
Zappasodi et al. | In vitro assays for effector T cell functions and activity of immunomodulatory antibodies | |
Aguiló et al. | Protein kinase C-θ is required for NK cell activation and in vivo control of tumor progression | |
MX2022015611A (es) | Ensayo basado en células para determinar la actividad de destrucción de tumores in vitro de células inmunitarias que expresan antígeno quimérico. | |
Rappolee et al. | Toxic stress prioritizes and imbalances stem cell differentiation: implications for new biomarkers and in vitro toxicology tests | |
Xystrakis et al. | Impact of donation mode on the proportion and function of T lymphocytes in the liver | |
González-González et al. | Validation of an ADCC assay using human primary natural killer cells to evaluate biotherapeutic products bearing an Fc region |